Barclays
TLOG

Barclays’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Barclays’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,290
Closed -$11K – 7966
2014
Q2 		$11K Buy
2,290
+2,192
+2,237% +$12.4K ﹤0.01% 6812
2014
Q1 		$1K Buy
+98
New +$884 ﹤0.01% 7524

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Barclays's TLOG Position: Q3 2014 in Review

Barclays sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q3 2014, closing a stake of 2,290 shares — an estimated $11K sold.

Barclays first reported a position in TLOG in Q1 2014 and held it in 2 quarters. The position peaked at $11K in Q2 2014. 25 funds tracked by Wall St. Rank hold TLOG as of Q3 2014.

  • Barclays reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q3 2014 after selling out during the quarter.
  • Barclays sold 2,290 TetraLogic Pharmaceuticals Corporation shares in Q3 2014, an estimated $11K.
  • Barclays first reported a position in TetraLogic Pharmaceuticals Corporation in Q1 2014 and held it in 2 quarters.
  • Barclays's TetraLogic Pharmaceuticals Corporation position peaked at $11K in Q2 2014.
  • 25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q3 2014.

Based on Barclays's 13F filing for Q3 2014, filed 14 Nov 2014.